Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:33:39.425Z.
Calculation as of: 2026-10-06T22:33:39.425Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$153.58M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.64M
EV/EBIT Ratio
N/A
TTM Avg
18.14x
3Y Avg
8.57x
5Y Avg
7.17x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Neuronetics, Inc. (STIM)vs › | $153.79M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.22M | N/A | 189.93x | 95.49x | 94.46x |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | N/A | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | N/A | 18.14x | 8.57x | 7.17x |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
